Classic Hodgkin Lymphoma Clinical Trials

13 recruitingLast updated: June 18, 2026

There are 13 actively recruiting classic hodgkin lymphoma clinical trials across 3 countries. Studies span Phase 2, Phase 1, Not Applicable. Top locations include Seattle, Washington, United States, Duarte, California, United States, Hackensack, New Jersey, United States. Updated daily from ClinicalTrials.gov.


Classic Hodgkin Lymphoma Trials at a Glance

13 actively recruiting trials for classic hodgkin lymphoma are listed on ClinicalTrialsFinder across 6 cities in 3 countries. The largest study group is Phase 2 with 11 trials, with the heaviest enrollment activity in Seattle, Duarte, and Hackensack. Lead sponsors running classic hodgkin lymphoma studies include University of Washington, City of Hope Medical Center, and Children's Oncology Group.

Browse classic hodgkin lymphoma trials by phase

Treatments under study

About Classic Hodgkin Lymphoma Clinical Trials

Looking for clinical trials for Classic Hodgkin Lymphoma? There are currently 8 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Classic Hodgkin Lymphoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Classic Hodgkin Lymphoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 113 of 13 trials

Recruiting
Not Applicable

Pilot Study of Bone Mineral Density Changes During Anti-PD-1 Immunotherapy

Non-small Cell Lung CancerMelanoma (Skin Cancer)Invasive Mammary Carcinoma+5 more
Jessica Mezzanotte Sharpe25 enrolled1 locationNCT07555210
Recruiting

A Study About How Blood Cell Growth Patterns Relate to Heart Health After Treatment for Hodgkin Lymphoma

Classic Hodgkin LymphomaCardiovascular DisorderClonal Hematopoiesis
Children's Oncology Group190 enrolled32 locationsNCT05705531
Recruiting
Phase 2

Pianzumab Combined With AVD Regimen in the Treatment of Newly-diagnosed Advanced Classic Hodgkin Lymphoma

Classic Hodgkin Lymphoma
Sun Yat-sen University108 enrolled1 locationNCT05949931
Recruiting
Phase 2

Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma

B-cell Non Hodgkin LymphomaBurkitt LymphomaHigh Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements+6 more
University of Washington18 enrolled1 locationNCT07097363
Recruiting
Phase 2

Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Standard Treatment

Classic Hodgkin Lymphoma
City of Hope Medical Center23 enrolled1 locationNCT07275216
Recruiting
Phase 2

Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With Advanced Hodgkin Lymphoma

Classic Hodgkin LymphomaAdvanced Hodgkin LymphomaLugano Classification Stage III Hodgkin Lymphoma AJCC v8+1 more
University of Washington125 enrolled5 locationsNCT06745076
Recruiting
Phase 2

Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma

Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsRefractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsRecurrent Grade 3b Follicular Lymphoma+19 more
David Bond, MD37 enrolled1 locationNCT05821088
Recruiting
Phase 2

Brentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed/Refractory Classical Hodgkin Lymphoma

Relapsed Classic Hodgkin Lymphoma
City of Hope Medical Center31 enrolled5 locationsNCT04561206
Recruiting
Phase 2

Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously Treated With Brentuximab Vedotin or Checkpoint Inhibitors

Recurrent Classic Hodgkin LymphomaRefractory Classic Hodgkin Lymphoma
Emory University46 enrolled2 locationsNCT05039073
Recruiting
Phase 2

MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma

Classic Hodgkin LymphomaAutologous Stem Cell Transplant
Masonic Cancer Center, University of Minnesota28 enrolled1 locationNCT06377540
Recruiting
Phase 1Phase 2

A Study of AK129 With or Without AK117 in PD(L)1-refractory Classic Hodgkin Lymphoma

Classic Hodgkin Lymphoma
Akeso280 enrolled1 locationNCT06642792
Recruiting
Phase 1Phase 2

A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies

Triple-Negative Breast CancerOvarian CancerCervical Cancer+7 more
Innolake Biopharm200 enrolled1 locationNCT05955105
Recruiting
Phase 2

Azacitidine Plus PD-1 Therapy for R/R Hodgkin Lymphoma

Refractory Classic Hodgkin LymphomaRelapsed Classic Hodgkin Lymphoma
Navy General Hospital, Beijing40 enrolled1 locationNCT06190067